Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: Inhibition by histamine H3 and H4 receptor activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 3, 2012, Pages 568-577

  Chan, Noel Yan Ki ^a   Robador, Pablo A ^a   Levi, Roberto ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 943931; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; HISTAMINE AGONIST; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H4 RECEPTOR; HISTAMINE H4 RECEPTOR AGONIST; JNJ 5207852; NATRIURETIC FACTOR; NESIRITIDE; NORADRENALIN; PHOSPHODIESTERASE III; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CARDIAC SYMPATHETIC NEURON; CARDIAC SYMPATHETIC OVERSTIMULATION; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; GUINEA PIG; HEART FAILURE; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYMPATHETIC NERVE CELL; SYNAPTOSOME;

ANIMALS; CALCIUM; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; GUINEA PIGS; HEART; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NEURONS; NOREPINEPHRINE; PC12 CELLS; PROTEIN KINASE INHIBITORS; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H3; SYMPATHETIC NERVOUS SYSTEM; SYNAPTOSOMES; TRANSFECTION;

EID: 84869210286     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.198747     Document Type: Article

References (44)

1. Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, Aluisio L, Lord B, Mazur C, Pudiak CM, et al. (2004) Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 143:649-661. (Pubitemid 39524283)
2. Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148-2159.
3. Chan NY, Seyedi N, Takano K, and Levi R (2012) An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation 125:298-307.
4. Connelly WM, Shenton FC, Lethbridge N, Leurs R, Waldvogel HJ, Faull RL, Lees G, and Chazot PL (2009) The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 157:55-63.
5. Cowart MD, Altenbach RJ, Liu H, Hsieh GC, Drizin I, Milicic I, Miller TR, Witte DG, Wishart N, Fix-Stenzel SR, et al. (2008) Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J Med Chem 51:6547-6557.
6. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, et al. (2005) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111:2469-2476. (Pubitemid 40696135)
7. Esler M and Kaye D (2000) Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev 5:17-25. (Pubitemid 30301508)
8. Fujimura M, Akaike M, Iwase T, Yoshida S, Sumitomo Y, Yagi S, Ikeda Y, Hashizume S, Aihara K, Nishiuchi T, et al. (2009) Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure. Acta Cardiol 64:589-595.
9. Gill RM, Braz JC, Jin N, Etgen GJ, and Shen W (2007) Restoration of impaired endothelium-dependent coronary vasodilation in failing heart: role of eNOS phosphorylation and CGMP/cGK-I signaling. Am J Physiol Heart Circ Physiol 292:H2782-H2790. (Pubitemid 47084527)
10. Grassi G, Seravalle G, Quarti-Trevano F, and Dell'oro R (2009) Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. Curr Vasc Pharmacol 7:137-145.
11. Hashikawa-Hobara N, Chan NY, and Levi R (2012) Histamine 3 receptor activation reduces the expression of neuronal angiotensin II type 1 receptors in the heart. J Pharmacol Exp Ther 340:185-191.
12. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, and Saitoh Y (1979) Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 211:26-30. (Pubitemid 10201537)
13. Hou Y, Lascola J, Dulin NO, Ye RD, and Browning DD (2003) Activation of cGMP-dependent protein kinase by protein kinase C. J Biol Chem 278:16706-16712. (Pubitemid 36799535)
14. 3 receptors in the human heart. Circ Res 77:206-210.
15. Kitbunnadaj R, Hashimoto T, Poli E, Zuiderveld OP, Menozzi A, Hidaka R, de Esch IJ, Bakker RA, Menge WM, Yamatodani A, et al. (2005) N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J Med Chem 48:2100-2107. (Pubitemid 40396337)
16. 3 receptor drugs. Nat Rev Drug Discov 4:107-120.
17. 3 receptors: a new frontier in myocardial ischemia. J Pharmacol Exp Ther 292:825-830.
18. Lewis RV and McDevitt DG (1986) Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol 1:343-361. (Pubitemid 17170242)
19. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, and Leurs R (2005) Evaluation of histamine H1, H2, and H3 receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective histamine H4 receptor agonist. J Pharmacol Exp Ther 314:1310-1321. (Pubitemid 41205997)
20. Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N, et al. (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 59:420-426. (Pubitemid 32179918)
21. Liu H and Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501-1510. (Pubitemid 28548563)
22. Meredith IT, Broughton A, Jennings GL, and Esler MD (1991) Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325: 618-624.
23. Molkentin JD (2003) A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest 111:1275-1277.
24. Moretto M, López FJ, and Negro-Vilar A (1993) Nitric oxide regulates luteinizing hormone-releasing hormone secretion. Endocrinology 133:2399-2402. (Pubitemid 23324754)
25. 2+ channels. J Pharmacol Exp Ther 326:871-878.
26. Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, et al. (2001) Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296:1058-1066. (Pubitemid 32187382)
27. Munagala VK, Burnett JC Jr, and Redfield MM (2004) The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 29:707-769. (Pubitemid 39488317)
28. Nakaya M, Takeuchi N, and Kondo K (2004) Immunohistochemical localization of histamine receptor subtypes in human inferior turbinates. Ann Otol Rhinol Laryngol 113:552-557. (Pubitemid 38902552)
29. Nijmeijer S, de Graaf C, Leurs R, and Vischer HF (2012) Molecular pharmacology of histamine H4 receptors. Front Biosci 17:2089-2106.
30. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, and de Breyne B (1994) Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 46:191-196. (Pubitemid 24137425)
31. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, et al. (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32-43.
32. Oda T, Morikawa N, Saito Y, Masuho Y, and Matsumoto S (2000) Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275:36781-36786. (Pubitemid 32002087)
33. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, and Kukin ML. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468-1475.
34. Schömig A (1990) Catecholamines in myocardial ischemia. Systemic and cardiac release. Circulation 82:II13-II22.
35. 3 receptor-induced attenuation of norepinephrine exocytosis: a decreased PKA activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther 312:272-280.
36. 2 receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings. Mediation by autocrine/paracrine mechanisms. Circ Res 81:774-784.
37. 3 receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc Natl Acad Sci U S A 99:501-506.
38. Simon T, Becker R, Voss F, Bikou O, Hauck M, Licka M, Katus HA, and Bauer A (2008) Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events. Clin Res Cardiol 97:306-309. (Pubitemid 351725056)
39. Springer J, Azer J, Hua R, Robbins C, Adamczyk A, McBoyle S, Bissell MB, and Rose RA (2012) The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors. J Mol Cell Cardiol 52:1122-1134.
40. Thireau J, Karam S, Fauconnier J, Roberge S, Cassan C, Cazorla O, Aimond F, Lacampagne A, Babuty D, and Richard S (2012) Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity. Cardiovasc Res 95:59-68.
41. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, and Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655-663. (Pubitemid 38364624)
42. Watanabe T, Satoo H, Kohara K, Takami R, Motoyashiki T, Morita T, and Ueki H (2004) Orthovanadate stimulates cAMP phosphodiesterase 3 activity in isolated rat hepatocytes through mitogen-activated protein kinase activation dependent on cAMP-dependent protein kinase. Biol Pharm Bull 27:789-796. (Pubitemid 41701790)
43. Wijkander J, Landström TR, Manganiello V, Belfrage P, and Degerman E (1998) Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology 139:219-227. (Pubitemid 28166313)
44. Zhu Y, Michalovich D, Wu H, Tan KB, Dytko GM, Mannan IJ, Boyce R, Alston J, Tierney LA, Li X, et al. (2001) Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 59:434-441. (Pubitemid 32179920)